Fidelity SPDR Advertisement
Home > Boards > US OTC > Biotechs >

Amarantus BioScience Holdings, Inc. (AMBS)

Add AMBS Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator dshade, r00kie, joboggi, Sir Francelote, Rosym
Search This Board:
Last Post: 9/18/2014 4:51:02 AM - Followers: 719 - Board type: Free - Posts Today: 2


Amarantus BioScience Holdings, Inc.

Amarantus is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis. The company has licensed Eltoprazine, a Phase 2B ready Parkinsons Levadopa induced Dyskinesia. The company has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test®") for Alzheimer's Disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. The Company also owns intellectual property rights for the diagnosis of Parkinson's Disease ("NuroPro") and the discovery of neurotrophic facotrs ("PhenoGuard"). For further information, please visit www.Amarantus.comor connect with the company on FacebookTwitter, LinkedIn & Google+




Amarantus Provides Program Update on Phase 2b Eltoprazine for Parkinson's Disease and Adult ADHD
Sept 17, 2014    8:00 a.m.
Amarantus Completes Enrollment of 72 Patient LP-002 Clinical Study for Alzheimer's Blood Diagnostic LymPro Test(R)
Sept 12, 2014   10:30 a.m.
Amarantus to Present Orphan Ocular Data at Targeting Ocular Disorders Conference 2014
Sept 10, 2014   1:00 p.m.
Amarantus Announces Positive MANF Ocular Toxicology Data
Sept. 9, 2014   8:31 a.m.
Amarantus to Present at Sachs Associates 14th Annual Biotech in Europe Forum for Global Partnering and Investment

Sept 4, 2014   9:00 a.m.
Initiating Studies for CLIA Launch at Icon Central Laboratories
September 2nd, 2014   8:00 am
Amarantus BioScience Holdings, Inc. - "Initiating Studies for CLIA Launch at Icon Central Laboratories"
Sept 2, 2014   8:26 a.m.
Amarantus Initiates CLIA Development of Alzheimer's Blood Diagnostic LymPro Test(R) at ICON Central Laboratories
Sept 2, 2014   6:00 a.m. 
Amarantus Appoints Iain Ross to Board of Directors
Aug. 29, 2014   7:57 a.m. 
Amarantus Reports Second Quarter 2014 Financial Results, Announces Business Update Call
Aug. 27, 2014   9:00 a.m  
Amarantus to Present at Upcoming Investor Conferences
Aug. 19, 2014   8:42 A.M. 
Amarantus Exercises Option to License Intellectual Property From University of Miami Bascom Palmer Eye Institute for Use of MANF in Retinal Disorders
Aug. 15, 2014   8:11 A.M. 
Amarantus BioScience Holdings, Inc. "Preparing Amarantus for the Up-list in 2H-14: Capital Markets Strategy"
Aug. 11, 2014   8:03 a.m. 
Amarantus Enters Into Research Collaboration With the Buck Institute for Research on Aging for MANF
Aug. 11, 2014   8:01 A.M. ET



SNNLive - Amarantus BioScience Holdings, Inc.
Published on June 21, 2014

SNNLive - Amarantus BioScience Holdings, Inc.
Published on May 21, 2014



Medical Dictionary (some often-used terms in AMBS PRs)

The substania nigra is an area of pigmented cells in the midbrain which is responsible for producing the neurotransmitter dopamine. This section of the brain plays an important role in the control of movement, and it also appears to interact in the process of addiction, as well. If you view a brain in cross-section, the substantia nigra is located in the midbrain, right at the tip of the brainstem.
The striatum is also called the striate body. It includes the caudate nucleus and the lentiform nucleus. The term striatum (striate) refers to the layered appearance of bands of gray matter that course from one of these nuclei to the other and represent the connections between them.
In living tissues, reinnervation describes the process by which post-synaptic neurons form new synapses or increase existing synaptic efficacy in order to compensate for a lack of pre-synaptic input from dead or otherwise dysfunctional pre-synaptic neurons.

Glial cell-derived neurotrophic factor, also known as GDNF is a protein that, in humans, is encoded by the GDNF gene.[1] GDNF is a small protein that potently promotes the survival of many types of neurons.[2
Myocardial infarction (MI) or acute myocardial infarction (AMI), commonly known as a heart attack


  Pertinent Terms of Service

A. Is unlawful, threatening, abusive, harassing, defamatory, libelous, vulgar, hateful, deceptive, fraudulent, invasive of another's privacy, tortious, contains explicit or graphic descriptions or accounts of sexual acts (including but not limited to sexual language of a violent or threatening nature directed at another individual or group of individuals), or otherwise violates our rules or policies; This includes signatures as well. 
B. Attacks, verbally or otherwise, any other user, the website, any non-public figure, or any agents or employees of iHub; This includes signatures as well.
C. Victimizes, harasses, degrades, or intimidates an individual or group of individuals on the basis of religion, gender, sexual orientation, race, ethnicity, age, or disability; This includes signatures as well.

 A reminder, if your post is removed and you think it should be restored go to mailbox, and then click on removed posts, and follow the directions. Post that talk about other members, or other companies violate the TOS. Those posts are routinely deleted. It is easy to talk about AMBS without talking about the posters or in most cases, other companies and products.


      Mr. Commissiong made a presentation on Sept. 12/14 at the Aegis Capital 2014                          Healthcare and Technology Conference at web cast live at 10:00 AM PT and
               available at .


smiley   Amarantus Bioscience Holdings, Inc. (otcqb:AMBS), a biotechnology company focused on the development of diagnostic and therapeutic interventions for Alzheimer's disease, Parkinson's disease and
orphan ophthalmological disorders, announced that Gerald E. Commissiong, President and CEO, is scheduled
to present at the 14th Annual Biotech in Europe Forum at the Congress Center in Basel, Switzerland. 
The presentation is scheduled for Wednesday, October 1st at 11:45 AM in the Darwin Room Mr. Commissiong's presentation will be web cast live and available on the company's web site at

Additional information about the conference may be found at Attendees who wish to meet with management one on one may contact our Investor Relations department at

angel  Dr. Roman Urfer, Chief Development Officer at NeuroAssets Sarl, will be presenting efficacy data for MANF in an undisclosed orphan ocular indication at Targeting Ocular Disorders 2014NeuroAssets is a Swiss-based neuroscience-focused consulting firm engaged by Amarantus to support the translational development of MANF. 
Dr. Urfer's presentation will be made at 3:40pm ET on October 6th, 2014 at the Westin Boston Waterfront Market in Boston, MA.

smiley  AMBS expect to complete the agreement with Big Pharma, partner by the end of the summer.



Company Information

Investor Relations

Transfer Agent

Amarantus BioScience Holdings, Inc.
c/o Janssen Labs @ QB3
953 Indiana Street
San Francisco, CA 94107

c/o ICS Corporate Services SA
29 quai du Mont Blanc
CH-1201 Geneva

Phone: (408) 737-2734
Fax: (408) 852-4427

Aimee Boutcher
Director of Investor Relations
Amarantus BioScience Holdings, Inc

408-737-2734 x101

VStock Transfer, LLC
77 Spruce Street, Suite 201
Cedarhurst, NY 11516

Attn: Allison Niccols

Phone: 212-828-8436
Toll-Free: 855-9VSTOCK
Fax: 646-536-3179


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
AMBS News: Initial Statement of Beneficial Ownership (3) 09/15/2014 05:00:14 PM
AMBS News: Initial Statement of Beneficial Ownership (3) 09/04/2014 06:56:01 PM
AMBS News: Initial Statement of Beneficial Ownership (3) 09/04/2014 04:07:28 PM
AMBS News: Current Report Filing (8-k) 09/02/2014 05:26:11 PM
AMBS News: Current Report Filing (8-k) 08/29/2014 08:36:44 AM
#108320  Sticky Note New or Potential investors in AMBS r00kie 09/08/14 04:02:27 PM
#108317  Sticky Note zoomboom 09/08/14 09:42:50 AM
#107220  Sticky Note About Amarantus BioScience, Inc. Rosym 08/07/14 04:32:28 PM
#104968  Sticky Note MJFF is firm with their notion that NFs joboggi 07/17/14 02:01:07 AM
#108560   this stock was JUST up at almost 20 joboggi 09/18/14 04:51:01 AM
#108559   Milestone, AMBS PAYS another company to get their joboggi 09/18/14 03:20:17 AM
#108558   Expecting substantial volatility through next week as the Solantey 09/17/14 11:02:32 PM
#108556   There are up days and down days. The veeets 09/17/14 05:51:37 PM
#108555   At one point he was given some degree Solantey 09/17/14 05:25:44 PM
#108554   $AMBS Amarantus scores a small victory in the zoomboom 09/17/14 04:56:39 PM
#108553   Thanks for pointing that out. Solantey 09/17/14 04:37:37 PM
#108552   Below .08 by tomorrow. Below .07 next week. dsw 09/17/14 03:55:29 PM
#108551   wow another 10% down today. Didnt think it dsw 09/17/14 03:52:47 PM
#108550   I was only agreeing about the chart and brharris 09/17/14 03:49:00 PM
#108549   lol, lwol, rofl. Eltoprazine study in 2015. not joboggi 09/17/14 02:57:41 PM
#108548   AMBS in the .08's??? What did I miss? sumotrader 09/17/14 02:39:04 PM
#108547   I don't need to watch and learn. My brharris 09/17/14 01:49:47 PM
#108546   Volume is low and the uptrend, extending back BBalls-N-CowTown 09/17/14 01:43:15 PM
#108545   Shake the tree. No guts no glory myersvodka 09/17/14 01:40:55 PM
#108544   Below .07 next week. Solantey 09/17/14 01:31:20 PM
#108543   For once I actually agree with you. And brharris 09/17/14 01:20:50 PM
#108542   Down down down, again? But why why why??? hometownJOE 09/17/14 01:12:17 PM
#108541   BOGUS! The issue is your statement "implies that 68-Tele 09/17/14 12:37:06 PM
#108540   That is the second piercing of the 200 joboggi 09/17/14 12:30:30 PM
#108539   I would bet that someone wrote to GC joboggi 09/17/14 12:26:38 PM
#108538   WRONG! "implies that they do not have any 68-Tele 09/17/14 12:13:16 PM
#108535   aha, yep, early 2015. It cannot really start joboggi 09/17/14 12:00:58 PM
#108533   WRONG! "by 2015" denotes occurrence either in 2014 68-Tele 09/17/14 11:56:58 AM
#108532   distortion starts when people start mixing purposefully A/S christjamin 09/17/14 11:41:51 AM
#108531   I'm convinced that Gerald could care less about Solantey 09/17/14 11:40:54 AM
#108530   Phase 2b PD LID clinical trial in the Rosym 09/17/14 11:37:49 AM
#108529   Has anything related to AMBS started even close joboggi 09/17/14 11:21:57 AM
#108528   They did not mention in the release that joboggi 09/17/14 11:17:52 AM
#108527   another chortle, and continued belly laughing. See, AMBS joboggi 09/17/14 11:15:25 AM
#108526   1. Request pre-IND meeting with the FDA joboggi 09/17/14 11:09:34 AM
#108525   hahahahahaha..Buddy, why do you waste your time replying christjamin 09/17/14 11:09:06 AM
#108524   Sometimes it takes a little bit of common Solantey 09/17/14 10:54:19 AM
#108523   Enjoying the ride! AMBS, I am with you 100%. Rosym 09/17/14 09:19:55 AM
#108522   Join the Money Train - AMBS breezy1 09/17/14 08:59:47 AM
#108521   I am still wondering why some people post christjamin 09/17/14 08:56:15 AM
#108520   Give the quote and time reference or REMOVE 68-Tele 09/17/14 08:18:07 AM
#108519   Eltoprazine Amarantus Provides Program Update on Phase 2b Eltoprazine Rosym 09/17/14 08:13:51 AM
#108518   Look again and listen to Call. zoomboom 09/17/14 08:11:41 AM
#108517   SAN FRANCISCO and GENEVA, Sept. 17, 2014 (GLOBE abbey1212 09/17/14 08:07:05 AM
#108516   Amarantus Provides Program Update on Phase 2b Eltoprazine a surfer 09/17/14 08:06:32 AM
#108515   "The ‘Fit for Purpose Flow Cytometry Assay Validation’ joboggi 09/17/14 05:14:54 AM
#108514   As I noted before, they do not have joboggi 09/17/14 05:03:49 AM
#108513   I found the reference in a few clicks. joboggi 09/17/14 04:16:53 AM
#108512   good dd is always important. I do my joboggi 09/17/14 03:51:10 AM
#108511   Well, that is a range, it has already joboggi 09/17/14 01:05:22 AM
#108510   email GC, he said it in his CC joboggi 09/17/14 01:01:11 AM
#108509   Appears to me that the six month chart Solantey 09/16/14 11:56:34 PM
#108508   All post not official been proved by Amarantus myersvodka 09/16/14 11:49:35 PM
#108507   This not confirmed by ambs and must be removed. myersvodka 09/16/14 11:43:26 PM